EXEL Exelixis, Inc. - Common Stock
$52,86
Prezzo · Ago 18, 2026
Fondamentali al Ago 5, 2026
Intervallo 52 sett.
$34–$58
80% of range
Rating Analisti
HOLD
26 analysts
Prezzo Obiettivo
$53
+0% upside
P/E (TTM)
18.4
ROE
37.3%
Margine di Profitto Netto
33.7%
Informazioni su Exelixis, Inc. - Common Stock Panoramica della società da Wikipedia
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Leggi di più
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
History
Exelixis was founded in 1994; the scientific founders were Spyridon Artavanis–Tsakonas, at Yale at that time, and Corey Goodman and Gerry Rubin who were then at the University of California, Berkeley. George Scangos joined the company as CEO in 1996. The business plan was to use model organisms (fruit flies, nematodes, and zebrafish) and functional genomics to identify pathways and biological targets that could be exploited in the fields of agriculture and medicine. It eventually set up a subsidiary, Exelixis Plant Sciences, for the agricultural work.
By 2000, Exelixis had left the radical exploratory phase behind and became focused on drug discovery and had a chemical library of 4 million compounds. The company went public that year, after withdrawing its offering the week before; it raised $118 million in a down market.
In 2002, the company signed a broad alliance with GSK to discover new drugs in the fields of cancer, inflammatory diseases, and vascular conditions; GSK paid it $30 million in cash, bought $14 million in stock at twice the market rate, and committed to providing Exelixis with $90 million in research funding; it also offered loan financing of up to $85 million.
By 2002, the company had limited its internal efforts to cancer, and had settled its strategy on discovering and developing drugs that could inhibit targeted small sets of tyrosine kinases that are needed for cancer formation, growth, and metastasis. The sets of TKs had been identified by means of its prior functional genomics work. This approach was controversial at the time; most companies try to selectively target just one protein in their discovery efforts.
In 2006, Exelixis partnered with Daiichi Sankyo on compounds that targeted mineralocorticoid receptors; esaxerenone was part of this collaboration. In 2007, the company partnered its MEK inhibitor program with Genentech; cobimetinib (at that time XL-518) was part of this collaboration. Exelixis had filed an IND on XL-518 prior to the partnership, committed to funding and running the Phase I trial, and retained rights to co-market it in the US.
In 2008, the company partnered its lead cancer drug candidate, XL-184 (which would become called cabozantinib) and another cancer candidate, XL-281, with Bristol Myers Squibb; BMS returned the rights to XL-184 to Exelixis in 2010 and returned the rights to other drug candidate in 2011.
In 2010, Scangos departed as CEO to take over at Biogen and the company appointed Michael M. Morrissey as president and CEO; Morrissey had joined the company in 2000 as Vice President of Discovery Research. At that time the company had eight drugs in clinical trials.
Exelixis' first drug approval came in 2012, when cabozantinib was approved for medullary thyroid cancer, an orphan indication. It was approved in Europe in 2014.
Exelixis invested heavily in exploring cabozantinib in other cancers, betting the future of the company on the drug. In 2014 the drug failed a Phase III trial in prostate cancer, and the company laid off 70% of its employees.
In 2015, Genentech and Exelixis won FDA approval for cobimetinib for certain forms of melanoma.
In March 2016, Exelixis licensed to Ipsen worldwide rights (outside the US, Canada, and Japan) to market cabozantinib.
In April 2016, the FDA granted approval for marketing the tablet formulation as a second line treatment for kidney cancer and the same was approved in Europe in October of that year.
In December 2017, the FDA granted approval for the use of cabozantinib for first line treatment of kidney cancer and in 2018 approval for first-line treatment was approved in Europe.
Finance
Pricing
Cabometyx (cabozantinib)
In 2023, the Institute for Clinical and Economic Review (ICER) identified Cabometyx (cabozantinib) as one of five high-expenditure drugs that experienced significant net price increases without new clinical evidence to justify the hikes. Specifically, Cabometyx's wholesale acquisition cost rose by 7.5%, leading to an additional $86 million in costs to U.S. payers.
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
EXEL Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$52.86
Capitalizzazione di Mercato
$13.41B
P/E (TTM)
18.4
EPS (TTM)
$2.78
Ricavi (TTM)
$2.32B
Rendimento div.
—
ROE
37.3%
D/E Debito/Patrimonio
—
Intervallo 52 sett.
$34 – $58
EXEL Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
Configure
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Ricavi e Utile Netto
$2.32B
2016-12-31
→
2026-01-02
EPS
$2.78
2017-12-29
→
2026-01-02
Flusso di cassa libero
$876M
2017-12-29
→
2026-01-02
Margini
33.7%
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
Metrica
Tendenza 5 anni
EXEL
Mediana dei peer
P/E (TTM)
18.4
28.5
P/S (TTM)
5.8
20.1
P/B
6.2
12.9
Price / FCF (Prezzo / FCF)
15.3
—
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
Metrica
Tendenza 5 anni
EXEL
Mediana dei peer
Operating Margin (Margine Operativo)
37.6%
—
Net Profit Margin (Margine di Profitto Netto)
33.7%
-48.4%
ROA
27.0%
-28.4%
ROE
37.3%
-49.2%
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
Metrica
Tendenza 5 anni
EXEL
Mediana dei peer
Current Ratio (Rapporto corrente)
3.6
5.0
Quick Ratio
3.3
—
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
Metrica
Tendenza 5 anni
EXEL
Mediana dei peer
Revenue YoY (Ricavi YoY)
7.0%
—
Revenue CAGR 3Y (CAGR Ricavi 3Y)
12.9%
—
Revenue CAGR 5Y (CAGR Ricavi 5Y)
18.6%
—
EPS YoY
58.0%
—
Net Income YoY (Utile Netto YoY)
50.1%
—
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
Metrica
Tendenza 5 anni
EXEL
Mediana dei peer
EXEL Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
COMPRA
26 analisti
- Acquisto forte 5 19,2%
- Compra 8 30,8%
- Mantieni 12 46,2%
- Vendi 1 3,8%
- Vendita forte 0 0,0%
Target Price a 12 Mesi
16 analisti · 2026-08-13
Mediana
$52.00
Ora
$52.86
Basso
$41.00
Alto
$66.00
Target mediano
$52.00
-1,6%
Target medio
$52.94
+0,1%
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
0.08%
| Periodo | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|
| 30 Giugno 2026 | $0.82 | $0.80 | 0.02% |
| 31 Marzo 2026 | $0.79 | $0.72 | 0.07% |
| 31 Dicembre 2025 | $0.88 | $0.82 | 0.06% |
| 30 Settembre 2025 | $0.69 | $0.63 | 0.06% |
| 30 Giugno 2025 | $0.65 | $0.57 | 0.08% |
| 31 Marzo 2025 | $0.55 | $0.37 | 0.18% |
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| EXEL | $11.44B | 15.7 | 7.0% | 33.7% | 37.3% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | — |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | — |
| BMRN | $11.43B | 33.0 | 12.9% | 10.8% | 5.8% | — |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | — |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | — |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | — |
| PRAX | $7.43B | -21.9 | 249.5% | — | -47.3% | — |
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | — |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico 16
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B | $988M | $968M | $854M | $452M | $191M | $37M | |
| Cost of Revenue | $84M | $76M | $73M | $58M | $53M | $36M | $33M | $26M | $15M | $7M | $4M | |
| R&D Expense | $825M | $910M | $1.04B | $892M | $694M | $548M | $337M | $182M | $112M | $96M | $96M | |
| SG&A Expense | $519M | $492M | $543M | $460M | $402M | $293M | $228M | $206M | $159M | $116M | $57M | |
| Operating Expenses | $1.45B | $1.56B | $1.66B | $1.41B | $1.15B | $877M | $598M | $415M | $287M | $220M | $159M | |
| Operating Income | $872M | $605M | $171M | $201M | $287M | $110M | $369M | $439M | $166M | $-28M | $-121M | |
| Interest Expense | · | · | · | · | · | · | $0 | $0 | $9M | $33M | $41M | |
| Other Non-op | $-198.0K | $-133.0K | $93.0K | $-197.0K | $-184.0K | $912.0K | $680.0K | $397.0K | $-4M | $5M | $-381.0K | |
| Pretax Income | · | · | · | · | · | $131M | $398M | $452M | $159M | $-70M | $-162M | |
| Income Tax | $159M | $160M | $50M | $52M | $63M | $19M | $77M | $-238M | $4M | $0 | $55.0K | |
| Net Income | $783M | $521M | $208M | $182M | $231M | $112M | $321M | $690M | $154M | $-70M | $-162M | |
| EPS (Basic) | $2.88 | $1.80 | $0.65 | $0.57 | $0.73 | $0.36 | $1.06 | $2.32 | $0.52 | · | $-0.77 | |
| EPS (Diluted) | $2.78 | $1.76 | $0.65 | $0.56 | $0.72 | $0.35 | $1.02 | $2.21 | $0.49 | · | $-0.77 | |
| Shares (Basic) | 271,567,000 | 290,030,000 | 318,151,000 | 321,526,000 | 314,884,000 | 308,271,000 | 302,584,000 | 297,892,000 | 293,588,000 | · | 209,227,000 | |
| Shares (Diluted) | 281,863,000 | 296,132,000 | 321,464,000 | 324,556,000 | 322,359,000 | 318,001,000 | 315,009,000 | 312,803,000 | 312,003,000 | · | 209,227,000 | |
| EBITDA | $901M | $633M | $197M | $222M | $300M | $119M | $378M | $444M | $167M | · | · |
Stato Patrimoniale 27
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $482M | $217M | $263M | $501M | $647M | $319M | $267M | $315M | $183M | $152M | $142M | |
| Short-term Investments | $577M | $894M | $732M | $807M | $820M | $887M | $586M | $379M | $205M | $268M | · | |
| Receivables | $287M | $265M | $237M | $215M | $283M | $161M | $119M | $163M | $77M | $40M | · | |
| Inventory | $22M | $22M | $17M | $33M | $27M | $21M | $13M | $10M | $7M | $3M | · | |
| Prepaid Expense | $76M | $68M | $68M | $62M | $58M | $57M | $27M | $31M | $9M | $5M | · | |
| Current Assets | $1.44B | $1.47B | $1.32B | $1.62B | $1.83B | $1.45B | $1.01B | $897M | $485M | $469M | · | |
| PP&E (Net) | $99M | $119M | $129M | $111M | $104M | $67M | $49M | $51M | $26M | $2M | · | |
| PP&E (Gross) | $231M | $220M | $209M | $171M | $145M | $102M | $74M | $68M | $49M | $27M | · | |
| Accum. Depreciation | $132M | $101M | $80M | $61M | $41M | $35M | $26M | $17M | $23M | $25M | · | |
| Goodwill | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | · | |
| Other Non-current Assets | · | · | · | · | $131M | $73M | $53M | $8M | $12M | $1M | · | |
| Total Assets | $2.84B | $2.95B | $2.94B | $3.07B | $2.62B | $2.14B | $1.89B | $1.42B | $655M | $596M | · | |
| Accounts Payable | $30M | $38M | $34M | $33M | $24M | $24M | $12M | $11M | $10M | $7M | · | |
| Short-term Debt | · | · | · | · | · | · | · | · | $0 | $80M | · | |
| Current Liabilities | $406M | $404M | $394M | $324M | $338M | $205M | $143M | $105M | $115M | $269M | · | |
| Capital Leases | $173M | $191M | $190M | $190M | $51M | $49M | $48M | $12M | $15M | · | · | |
| Other Non-current Liabilities | $104M | $109M | $94M | $69M | $8M | $721.0K | $2M | $1M | $2M | $541.0K | · | |
| Total Liabilities | $683M | $703M | $678M | $583M | $406M | $258M | $200M | $135M | $370M | $506M | · | |
| Long-term Debt | · | · | · | · | · | · | · | · | $0 | $189M | · | |
| Total Debt | · | · | · | · | · | · | · | · | $0 | · | · | |
| Common Stock | $262.0K | $282.0K | $303.0K | $324.0K | $319.0K | $312.0K | $305.0K | $300.0K | $296.0K | $290.0K | · | |
| Paid-in Capital | $2.23B | $2.34B | $2.44B | $2.54B | $2.43B | $2.32B | $2.24B | $2.17B | $2.11B | $2.07B | · | |
| Retained Earnings | $-77M | $-99M | $-173M | $-34M | $-217M | $-448M | $-559M | $-880M | $-1.83B | $-1.98B | · | |
| AOCI | $3M | $-1M | $-4M | $-15M | $-758.0K | $4M | $3M | $-701.0K | $-347.0K | $-416.0K | · | |
| Stockholders' Equity | $2.16B | $2.24B | $2.26B | $2.49B | $2.21B | $1.88B | $1.69B | $1.29B | $285M | $89M | $-141M | |
| Liabilities + Equity | $2.84B | $2.95B | $2.94B | $3.07B | $2.62B | $2.14B | $1.89B | $1.42B | $655M | $596M | · | |
| Shares Outstanding | 262,483,000 | 281,732,000 | 302,793,000 | 323,951,000 | 318,842,000 | 311,627,000 | 304,831,000 | 299,876,000 | 296,209,000 | 289,923,798 | 227,960,943 |
Flusso di cassa 17
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $29M | $29M | $26M | $21M | $14M | $9M | $8M | $5M | $1M | $1M | $1M | |
| Stock-based Comp | $113M | $94M | $106M | $108M | $120M | $105M | $57M | $41M | $24M | $23M | $22M | |
| Deferred Tax | $126M | $-59M | $-133M | $-60M | $47M | $15M | $71M | $-244M | $0 | $0 | $0 | |
| Restructuring | $21M | $34M | $0 | $0 | · | · | · | $0 | $-32.0K | $63M | $1M | |
| Other Non-cash | $-167M | $116M | $127M | $112M | $-10M | $-32M | $70M | $-76M | $-14M | · | · | |
| Operating Cash Flow | $884M | $700M | $333M | $363M | $401M | $209M | $527M | $416M | $166M | $206M | $-141M | |
| CapEx | $8M | $28M | $40M | $28M | $54M | $30M | $13M | $33M | $21M | $2M | $447.0K | |
| Investing Cash Flow | $350M | $-117M | $-27M | $-524M | $-43M | $-131M | $-587M | $-298M | $37M | $-216M | $50M | |
| Net Debt Issued | · | · | · | · | · | · | $0 | $0 | $-186M | · | · | |
| Stock Issued | · | · | · | · | · | · | · | · | $0 | $0 | $146M | |
| Stock Repurchased | $948M | $652M | $550M | $0 | $0 | · | · | · | · | · | · | |
| Net Stock Activity | $-948M | $-652M | $-550M | · | · | · | · | · | $0 | · | · | |
| Financing Cash Flow | $-970M | $-629M | $-546M | $586.0K | $-15M | $-25M | $13M | $10M | $-170M | $20M | $152M | |
| Net Change in Cash | $265M | $-46M | $-240M | $-161M | $343M | $53M | $-48M | $128M | $32M | $10M | $61M | |
| Taxes Paid | $155M | $170M | $186M | $128M | $13M | $4M | $8M | $11M | $538.0K | · | · | |
| Free Cash Flow | $876M | $672M | $293M | $335M | $337M | $179M | $514M | $382M | $144M | · | · | |
| Levered FCF | · | · | · | · | · | · | $514M | $382M | $136M | · | · |
Redditività 7
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 37.6% | 27.9% | 9.3% | 12.5% | 20.0% | 11.1% | 38.2% | 51.4% | 36.7% | · | · | |
| Net Margin | 33.7% | 24.0% | 11.3% | 11.3% | 16.1% | 11.3% | 33.2% | 80.8% | 34.1% | · | · | |
| Pretax Margin | · | · | · | · | · | 13.2% | 41.1% | 52.9% | 35.0% | · | · | |
| EBITDA Margin | 38.8% | 29.2% | 10.7% | 13.8% | 20.9% | 12.1% | 39.0% | 52.0% | 36.9% | · | · | |
| ROA | 27.0% | 17.7% | 6.9% | 6.4% | 9.7% | 5.6% | 19.4% | 66.4% | 24.7% | · | · | |
| ROE | 37.3% | 23.1% | 9.0% | 7.3% | 10.7% | 6.0% | 19.5% | 62.6% | 82.4% | · | · | |
| ROIC | · | · | · | · | · | 5.0% | 17.7% | 52.0% | 56.6% | · | · |
Liquidità e Solvibilità 4
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.6 | 3.6 | 3.3 | 5.0 | 5.4 | 7.1 | 7.1 | 8.5 | 4.2 | · | · | |
| Quick Ratio | 3.3 | 3.4 | 3.1 | 4.7 | 5.2 | 6.7 | 6.8 | 8.1 | 4.1 | · | · | |
| Debt / Equity | · | · | · | · | · | · | · | · | 0.0 | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | 19.1 | · | · |
Efficienza 3
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.7 | 0.6 | 0.6 | 0.6 | 0.5 | 0.6 | 0.8 | 0.7 | · | · | |
| Inventory Turnover | 3.8 | 3.8 | 2.9 | 1.9 | 2.2 | 2.1 | 2.9 | 3.2 | 3.0 | · | · | |
| Receivables Turnover | 8.4 | 8.6 | 8.1 | 6.5 | 6.5 | 7.1 | 6.9 | 9.8 | 7.4 | · | · |
Tassi di Crescita 9
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 7.0% | 18.5% | 13.6% | 12.3% | 45.3% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 12.9% | 14.8% | 22.8% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 18.6% | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 58.0% | 170.8% | 16.1% | -22.2% | 105.7% | · | · | · | · | · | · | |
| EPS CAGR 3Y | 70.6% | 34.7% | 22.9% | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 51.3% | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 50.1% | 150.9% | 14.0% | -21.1% | 106.7% | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 62.5% | 31.1% | 22.9% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 47.6% | · | · | · | · | · | · | · | · | · | · |
Valutazione (TTM) 14
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B | $988M | $968M | $854M | $452M | · | $37M | |
| Net Income TTM | $783M | $521M | $208M | $182M | $231M | $112M | $321M | $690M | $154M | · | $-162M | |
| Market Cap | $11.44B | $9.57B | $7.26B | $5.20B | $5.83B | $6.25B | $5.19B | $5.83B | $9.00B | · | · | |
| Enterprise Value | · | · | · | · | · | · | · | · | $8.62B | · | · | |
| P/E | 15.7 | 19.3 | 36.9 | 28.6 | 25.4 | 57.3 | 16.7 | 8.8 | 62.0 | · | -7.3 | |
| P/S | 4.9 | 4.4 | 4.0 | 3.2 | 4.1 | 6.3 | 5.4 | 6.8 | 19.9 | · | · | |
| P/B | 5.3 | 4.3 | 3.2 | 2.1 | 2.6 | 3.3 | 3.1 | 4.5 | 31.6 | · | · | |
| P / Tangible Book | 5.5 | 4.4 | 3.3 | 2.1 | 2.7 | 3.4 | · | · | · | · | · | |
| P / Cash Flow | 12.9 | 13.7 | 21.8 | 14.3 | 14.5 | 29.9 | 9.8 | 14.0 | 54.4 | · | · | |
| P / FCF | 13.1 | 14.3 | 24.8 | 15.5 | 17.3 | 35.0 | 10.1 | 15.2 | 62.3 | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | 51.6 | · | · | |
| EV / FCF | · | · | · | · | · | · | · | · | 59.6 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | 19.0 | · | · | |
| Earnings Yield | 6.4% | 5.2% | 2.7% | 3.5% | 3.9% | 1.7% | 6.0% | 11.4% | 1.6% | · | -13.7% |
Conto Economico 14
| Metrica | Tendenza | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $629M | $611M | $718M | $598M | $568M | $555M | $818M | $540M | $637M | $425M | $480M | $472M | $470M | $409M | $424M | $412M | |
| Cost of Revenue | $21M | $20M | $27M | $19M | $19M | $19M | $25M | $17M | $18M | $21M | $22M | $19M | $18M | $14M | $16M | $15M | |
| R&D Expense | $212M | $200M | $164M | $199M | $200M | $212M | $111M | $223M | $211M | $228M | $245M | $333M | $233M | $234M | $337M | $199M | |
| SG&A Expense | $148M | $140M | $161M | $124M | $135M | $137M | $81M | $112M | $132M | $114M | $131M | $138M | $142M | $131M | $119M | $115M | |
| Operating Expenses | $380M | $359M | $287M | $361M | $355M | $369M | $303M | $403M | $361M | $396M | $398M | $490M | $392M | $380M | $472M | $329M | |
| Operating Income | $248M | $251M | $431M | $237M | $214M | $187M | $516M | $136M | $276M | $29M | $82M | $-18M | $78M | $29M | $-48M | $83M | |
| Other Non-op | $54.0K | $219.0K | $207.0K | $-49.0K | $50.0K | $-245.0K | $-363.0K | $-29.0K | $-287.0K | $-89.0K | $-137.0K | $289.0K | $-5.0K | $-54.0K | $-337.0K | $-69.0K | |
| Income Tax | $51M | $57M | $43M | $59M | $46M | $46M | $128M | $37M | $67M | $12M | $18M | $5M | $19M | $8M | $-1M | $19M | |
| Net Income | $212M | $210M | $401M | $194M | $185M | $160M | $399M | $118M | $226M | $37M | $86M | $1M | $81M | $40M | $-30M | $73M | |
| EPS (Basic) | $0.85 | $0.81 | $1.57 | $0.72 | $0.68 | $0.57 | $1.43 | $0.41 | $0.78 | $0.12 | $0.28 | $0.00 | $0.25 | $0.12 | $-0.09 | $0.23 | |
| EPS (Diluted) | $0.82 | $0.79 | $1.49 | $0.69 | $0.65 | $0.55 | $1.39 | $0.40 | $0.77 | $0.12 | $0.28 | $0.00 | $0.25 | $0.12 | $-0.09 | $0.23 | |
| Shares (Basic) | 250,808,000 | 258,329,000 | -604,028,000 | 268,421,000 | 272,583,000 | 278,804,000 | -674,091,000 | 285,622,000 | 289,216,000 | 300,757,000 | -645,970,000 | 315,496,000 | 324,205,000 | 324,420,000 | 577,000 | 322,148,000 | |
| Shares (Diluted) | 259,675,000 | 267,322,000 | -609,119,000 | 278,535,000 | 284,393,000 | 288,177,000 | -676,699,000 | 291,478,000 | 293,974,000 | 305,530,000 | -651,367,000 | 319,247,000 | 327,305,000 | 326,279,000 | 136,000 | 325,066,000 | |
| EBITDA | $248M | $258M | · | $237M | $214M | $194M | · | $136M | $276M | $36M | · | $-18M | $78M | $36M | · | $83M |
Stato Patrimoniale 24
| Metrica | Tendenza | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $281M | $226M | $482M | $376M | $164M | $184M | $217M | $258M | $198M | $260M | · | $397M | $464M | $541M | · | $675M | |
| Short-term Investments | $558M | $551M | $577M | $612M | $627M | $848M | $894M | $931M | $804M | $704M | · | $707M | $802M | $773M | · | $872M | |
| Receivables | $322M | $329M | $287M | $310M | $292M | $282M | $265M | $270M | $397M | $241M | · | $248M | $233M | $234M | · | $215M | |
| Inventory | $29M | $27M | $22M | $27M | $23M | $25M | $22M | $21M | $21M | $21M | · | $25M | $29M | $30M | · | $27M | |
| Prepaid Expense | $60M | $76M | $76M | $77M | $74M | $59M | $68M | $70M | $58M | $67M | · | $67M | $62M | $61M | · | $53M | |
| Current Assets | $1.25B | $1.21B | $1.44B | $1.40B | $1.18B | $1.40B | $1.47B | $1.55B | $1.48B | $1.29B | · | $1.44B | $1.59B | $1.64B | · | $1.84B | |
| PP&E (Net) | $93M | $96M | $99M | $105M | $110M | $115M | $119M | $124M | $130M | $127M | · | $121M | $115M | $116M | · | $108M | |
| PP&E (Gross) | · | · | $231M | · | · | · | $220M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $132M | · | · | · | $101M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | · | $64M | $64M | $64M | · | $64M | |
| Other Non-current Assets | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $280M | |
| Total Assets | $2.49B | $2.59B | $2.84B | $2.82B | $2.68B | $2.84B | $2.95B | $2.96B | $2.77B | $2.80B | · | $2.98B | $3.14B | $3.14B | · | $2.96B | |
| Accounts Payable | $39M | $24M | $30M | $25M | $26M | $43M | $38M | $59M | $29M | $26M | · | $26M | $26M | $33M | · | $31M | |
| Current Liabilities | $362M | $371M | $406M | $374M | $336M | $399M | $404M | $394M | $346M | $373M | · | $377M | $340M | $328M | · | $302M | |
| Capital Leases | $166M | $170M | $173M | $176M | $180M | $187M | $191M | $194M | $198M | $201M | · | $191M | $195M | $187M | · | $160M | |
| Other Non-current Liabilities | $123M | $117M | $104M | $113M | $129M | $120M | $109M | $96M | $110M | $101M | · | $62M | $73M | $67M | · | $2M | |
| Total Liabilities | $650M | $658M | $683M | $663M | $645M | $706M | $703M | $685M | $653M | $676M | · | $629M | $615M | $588M | · | $470M | |
| Common Stock | $249.0K | $254.0K | $262.0K | $268.0K | $270.0K | $275.0K | $282.0K | $286.0K | $285.0K | $295.0K | · | $311.0K | $320.0K | $325.0K | · | $323.0K | |
| Paid-in Capital | $2.11B | $2.15B | $2.23B | $2.26B | $2.25B | $2.29B | $2.34B | $2.36B | $2.32B | $2.39B | · | $2.49B | $2.53B | $2.56B | · | $2.51B | |
| Retained Earnings | $-263M | $-216M | $-77M | $-106M | $-220M | $-163M | $-99M | $-90M | $-200M | $-259M | · | $-126M | $11M | $6M | · | $-4M | |
| AOCI | $-2M | $-415.0K | $3M | $4M | $1M | $2M | $-1M | $4M | $-5M | $-5M | · | $-14M | $-14M | $-9M | · | $-18M | |
| Stockholders' Equity | $1.84B | $1.94B | $2.16B | $2.16B | $2.03B | $2.13B | $2.24B | $2.28B | $2.12B | $2.13B | $2.26B | $2.35B | $2.53B | $2.56B | $2.49B | $2.49B | |
| Liabilities + Equity | $2.49B | $2.59B | $2.84B | $2.82B | $2.68B | $2.84B | $2.95B | $2.96B | $2.77B | $2.80B | · | $2.98B | $3.14B | $3.14B | · | $2.96B | |
| Shares Outstanding | 248,885,000 | 253,701,000 | 262,483,000 | 268,098,000 | 270,132,000 | 275,033,000 | 281,732,000 | 285,780,000 | 285,222,000 | 295,032,000 | 302,793,000 | 310,970,000 | 320,253,000 | 324,985,000 | 323,951,000 | 322,541,000 |
Flusso di cassa 12
| Metrica | Tendenza | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $7M | $7M | $8M | $7M | $7M | $7M | $10M | $7M | $7M | $6M | $7M | $6M | $6M | $7M | $6M | $6M | |
| Stock-based Comp | $33M | $29M | $45M | $31M | $36M | $26M | $12M | $23M | $25M | $19M | $24M | $40M | $25M | $17M | $26M | $37M | |
| Restructuring | · | · | $-13M | $20M | $0 | $0 | $34M | $96.0K | $475.0K | $33M | · | $0 | $0 | $0 | · | · | |
| Other Non-cash | · | $5M | · | · | · | $19M | · | · | · | $6M | · | · | · | $21M | · | · | |
| Operating Cash Flow | $308M | $252M | $425M | $290M | $49M | $211M | $377M | $271M | $120M | $69M | $11M | $117M | $121M | $84M | $74M | $110M | |
| CapEx | $7M | $2M | $-16M | $1M | $3M | $3M | $1M | $8M | $7M | $10M | $13M | $9M | $6M | $12M | $10M | $43.0K | |
| Investing Cash Flow | $91M | $-51M | $374M | $25M | $248M | $50M | $-28M | $-217M | $82M | $112M | $62M | $35M | $-74M | $-50M | $-246M | $-69M | |
| Stock Repurchased | $323M | $430M | $486M | $104M | $302M | $284M | $311M | $12M | $264M | $185M | $209M | $217M | $124M | $0 | $0 | $0 | |
| Net Stock Activity | · | $-430M | · | · | · | $-284M | · | · | · | $-185M | · | · | · | · | · | · | |
| Financing Cash Flow | $-344M | $-457M | $-529M | $-104M | $-316M | $-295M | $-289M | $6M | $-262M | $-184M | $-206M | $-220M | $-125M | $5M | $-2M | $-2M | |
| Net Change in Cash | $55M | $-256M | $270M | $212M | $-19M | $-34M | $60M | $60M | $-61M | $-3M | $-134M | $-68M | $-78M | $39M | $-174M | $39M | |
| Free Cash Flow | · | $250M | · | · | · | $208M | · | · | · | $59M | · | · | · | $72M | · | · |
Redditività 5
| Metrica | Tendenza | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 39.5% | 41.1% | · | 39.6% | 37.6% | 33.6% | · | 25.2% | 43.3% | 6.9% | · | -3.7% | 16.6% | 7.0% | · | 20.1% | |
| Net Margin | 33.7% | 34.5% | · | 32.4% | 32.5% | 28.7% | · | 21.9% | 35.5% | 8.8% | · | 0.22% | 17.3% | 9.8% | · | 17.8% | |
| EBITDA Margin | 39.5% | 42.3% | · | 39.6% | 37.6% | 35.0% | · | 25.2% | 43.3% | 8.4% | · | -3.7% | 16.6% | 8.7% | · | 20.1% | |
| ROA | 8.2% | 7.8% | · | 6.7% | 6.8% | 5.7% | · | 4.0% | 7.6% | 1.2% | · | 0.04% | 2.7% | 1.4% | · | 2.7% | |
| ROE | 10.9% | 10.3% | · | 8.7% | 8.9% | 7.5% | · | 5.1% | 9.7% | 1.6% | · | 0.04% | 3.3% | 1.7% | · | 3.2% |
Liquidità e Solvibilità 2
| Metrica | Tendenza | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 3.3 | · | 3.8 | 3.5 | 3.5 | · | 3.9 | 4.3 | 3.5 | · | 3.8 | 4.7 | 5.0 | · | 6.1 | |
| Quick Ratio | 3.2 | 3.0 | · | 3.5 | 3.2 | 3.3 | · | 3.7 | 4.0 | 3.2 | · | 3.6 | 4.4 | 4.7 | · | 5.8 |
Efficienza 3
| Metrica | Tendenza | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | |
| Inventory Turnover | 0.8 | 0.8 | · | 0.8 | 0.9 | 0.8 | · | 0.8 | 0.7 | 0.8 | · | 0.7 | 0.6 | 0.5 | · | 0.6 | |
| Receivables Turnover | 2.0 | 2.0 | · | 2.1 | 1.6 | 2.1 | · | 2.1 | 2.0 | 1.8 | · | 2.0 | 2.0 | 1.9 | · | 2.1 |
Valutazione (TTM) 10
| Metrica | Tendenza | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.41B | $2.33B | · | $2.26B | $2.30B | $2.16B | · | $2.07B | $2.00B | $1.78B | · | $1.76B | $1.71B | $1.60B | · | $1.52B | |
| Net Income TTM | $801M | $749M | · | $656M | $689M | $541M | · | $382M | $346M | $160M | · | $195M | $265M | $252M | · | $251M | |
| Market Cap | $13.90B | $11.13B | · | $10.75B | $12.47B | $9.51B | · | $7.42B | $6.41B | $7.00B | · | $6.79B | $6.12B | $6.31B | · | $5.06B | |
| P/E | 18.9 | 16.4 | · | 17.5 | 19.5 | 18.8 | · | 20.1 | 19.7 | 48.4 | · | 36.4 | 23.3 | 24.9 | · | 20.1 | |
| P/S | 5.8 | 4.8 | · | 4.8 | 5.4 | 4.4 | · | 3.6 | 3.2 | 3.9 | · | 3.9 | 3.6 | 4.0 | · | 3.3 | |
| P/B | 7.5 | 5.8 | · | 5.0 | 6.1 | 4.5 | · | 3.3 | 3.0 | 3.3 | · | 2.9 | 2.4 | 2.5 | · | 2.0 | |
| P / Tangible Book | 7.8 | 5.9 | · | 5.1 | 6.3 | 4.6 | · | 3.4 | 3.1 | 3.4 | · | 3.0 | 2.5 | 2.5 | · | 2.1 | |
| P / Cash Flow | · | 44.2 | · | · | · | 45.0 | · | · | · | 101.7 | · | · | · | 74.7 | · | · | |
| P / FCF | · | 44.5 | · | · | · | 45.6 | · | · | · | 118.4 | · | · | · | 87.1 | · | · | |
| Earnings Yield | 5.3% | 6.1% | · | 5.7% | 5.1% | 5.3% | · | 5.0% | 5.1% | 2.1% | · | 2.8% | 4.3% | 4.0% | · | 5.0% |
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
Conto Economico
| 2026-01-02 | 2025-01-03 | 2023-12-29 | 2022-12-30 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ricavi | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B |
| Margine Operativo % | 37.6% | 27.9% | 9.3% | 12.5% | 20.0% |
| Utile netto | $783M | $521M | $208M | $182M | $231M |
| EPS Diluito | $2.78 | $1.76 | $0.65 | $0.56 | $0.72 |
Stato Patrimoniale
| 2026-01-02 | 2025-01-03 | 2023-12-29 | 2022-12-30 | 2021-12-31 | |
|---|---|---|---|---|---|
| Rapporto corrente | 3.6 | 3.6 | 3.3 | 5.0 | 5.4 |
| Quick Ratio | 3.3 | 3.4 | 3.1 | 4.7 | 5.2 |
Flusso di cassa
| 2026-01-02 | 2025-01-03 | 2023-12-29 | 2022-12-30 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flusso di cassa libero | $876M | $672M | $293M | $335M | $337M |
Ultime notizie Notizie recenti che menzionano questa società
Segnali di trading Segnali recenti di acquisto/vendita con prezzo di entrata e rapporto rischio/rendimento
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
📊
Scegli le metriche che contano per te — fai clic sul ➕ accanto a qualsiasi riga nei Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Proprietari istituzionali (13F) 811 filer · $9.1B totale · Aggiornato al 30 Giugno 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Attività istituzionale — Q2 2026 vs trimestre precedente
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 135 (+27 vs trimestre precedente) | 61 (-13 vs trimestre precedente) | 240 (-1 vs trimestre precedente) | 274 (+16 vs trimestre precedente) | +39.8M |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $732.794.424 | 13.468.010 | 8,04% | Azioni |
| RENAISSANCE TECHNOLOGIES LLC | $730.617.099 | 13.427.993 | 8,01% | Azioni |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $655.266.268 | 12.043.122 | 7,19% | Azioni |
| VANGUARD CAPITAL MANAGEMENT LLC | $595.843.747 | 10.950.997 | 6,53% | Azioni |
| STATE STREET CORP | $542.471.563 | 9.970.071 | 5,95% | Azioni |
| FULLER & THALER ASSET MANAGEMENT, INC. | $485.848.030 | 8.929.389 | 5,33% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $362.702.104 | 6.664.894 | 3,98% | Azioni |
| D. E. Shaw & Co., Inc. | $281.389.313 | 5.171.647 | 3,09% | Azioni |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $237.550.034 | 4.365.926 | 2,60% | Azioni |
| TWO SIGMA INVESTMENTS, LP | $229.058.537 | 4.209.861 | 2,51% | Azioni |
| DIMENSIONAL FUND ADVISORS LP | $221.832.835 | 4.077.060 | 2,43% | Azioni |
| ASSETMARK, INC | $186.834.364 | 3.433.824 | 2,05% | Azioni |
| Stephens Investment Management Group LLC | $147.451.698 | 2.710.011 | 1,62% | Azioni |
| NORGES BANK | $146.301.199 | 2.688.866 | 1,60% | Azioni |
| FIRST TRUST ADVISORS LP | $138.383.701 | 2.543.353 | 1,52% | Azioni |
| Caisse de depot et placement du Quebec | $113.950.809 | 2.094.299 | 1,25% | Azioni |
| GOLDMAN SACHS GROUP INC | $106.578.308 | 1.958.800 | 1,17% | Azioni |
| AMERICAN CENTURY COMPANIES INC | $97.484.439 | 1.791.664 | 1,07% | Azioni |
| VANGUARD FIDUCIARY TRUST CO | $86.563.209 | 1.590.943 | 0,95% | Azioni |
| Caligan Partners LP | $84.512.985 | 1.553.262 | 0,93% | Azioni |
| MILLENNIUM MANAGEMENT LLC | $66.309.793 | 1.218.706 | 0,73% | Azioni |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $63.086.055 | 1.159.457 | 0,69% | Azioni |
| BANK OF AMERICA CORP /DE/ | $58.788.318 | 1.080.469 | 0,64% | Azioni |
| Robeco Institutional Asset Management B.V. | $56.032.453 | 1.029.819 | 0,61% | Azioni |
| ENVESTNET ASSET MANAGEMENT INC | $51.671.488 | 949.669 | 0,57% | Azioni |
| FMR LLC | $48.839.667 | 897.623 | 0,54% | Azioni |
| Gotham Asset Management, LLC | $48.569.794 | 892.663 | 0,53% | Azioni |
| Swedbank AB | $45.801.141 | 841.778 | 0,50% | Azioni |
| Allspring Global Investments Holdings, LLC | $44.544.520 | 825.510 | 0,49% | Azioni |
| Retirement Systems of Alabama | $44.107.739 | 810.655 | 0,48% | Azioni |
| BOOTHBAY FUND MANAGEMENT, LLC | $43.750.809 | 804.095 | 0,48% | Azioni |
| RAYMOND JAMES FINANCIAL INC | $41.924.320 | 770.526 | 0,46% | Azioni |
| Capital Impact Advisors, LLC | $41.061.268 | 754.664 | 0,45% | Azioni |
| BlackRock, Inc. | $40.753.525 | 749.008 | 0,45% | Azioni |
| RHUMBLINE ADVISERS | $35.723.294 | 656.559 | 0,39% | Azioni |
| CANADA PENSION PLAN INVESTMENT BOARD | $35.464.438 | 651.800 | 0,39% | Azioni |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $34.721.830 | 639.680 | 0,38% | Azioni |
| MARSHALL WACE, LLP | $34.322.590 | 630.814 | 0,38% | Azioni |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | $34.315.027 | 630.675 | 0,38% | Azioni |
| AMERIPRISE FINANCIAL INC | $32.255.716 | 592.827 | 0,35% | Azioni |
| BARCLAYS PLC | $31.502.574 | 578.985 | 0,35% | Azioni |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | $31.496.480 | 578.873 | 0,35% | Azioni |
| Arbejdsmarkedets Tillaegspension | $30.855.911 | 567.100 | 0,34% | Azioni |
| Pictet Asset Management Holding SA | $30.153.926 | 555.438 | 0,33% | Azioni |
| California Public Employees Retirement System | $29.366.600 | 539.728 | 0,32% | Azioni |
| CAPITAL FUND MANAGEMENT S.A. | $28.686.856 | 527.235 | 0,31% | Azioni |
| BNP PARIBAS FINANCIAL MARKETS | $28.655.734 | 526.663 | 0,31% | Azioni |
| JANUS HENDERSON GROUP PLC | $26.675.806 | 621.814 | 0,29% | Azioni |
| Woodline Partners LP | $26.411.049 | 485.408 | 0,29% | Azioni |
| Driehaus Capital Management LLC | $26.025.500 | 478.322 | 0,29% | Azioni |
| EULAV Asset Management | $25.901.500 | 476.043 | 0,28% | Azioni |
| Squarepoint Ops LLC | $25.774.398 | 473.707 | 0,28% | Azioni |
| Swiss National Bank | $25.648.874 | 471.400 | 0,28% | Azioni |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $25.156.355 | 462.348 | 0,28% | Azioni |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $24.600.555 | 452.133 | 0,27% | Azioni |
| IEQ CAPITAL, LLC | $24.580.697 | 451.768 | 0,27% | Azioni |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $23.831.580 | 438.000 | 0,26% | Azioni |
| Baird Financial Group, Inc. | $23.565.461 | 433.109 | 0,26% | Azioni |
| FRANKLIN RESOURCES INC | $23.480.472 | 431.547 | 0,26% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $23.347.331 | 429.100 | 0,26% | Opzione Call |
| Assenagon Asset Management S.A. | $23.324.098 | 428.673 | 0,26% | Azioni |
| BANK OF NOVA SCOTIA | $22.837.676 | 419.730 | 0,25% | Azioni |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $22.615.516 | 415.650 | 0,25% | Azioni |
| South Street Advisors LLC | $22.275.019 | 409.392 | 0,24% | Azioni |
| Bridgewater Associates, LP | $21.810.738 | 400.859 | 0,24% | Azioni |
| VICTORY CAPITAL MANAGEMENT INC | $21.480.143 | 394.783 | 0,24% | Azioni |
| ROYAL BANK OF CANADA | $20.031.000 | 368.153 | 0,22% | Azioni |
| SEI INVESTMENTS CO | $19.897.640 | 365.698 | 0,22% | Azioni |
| LAZARD ASSET MANAGEMENT LLC | $18.664.208 | 343.029 | 0,20% | Azioni |
| Nuveen, LLC | $18.299.226 | 336.321 | 0,20% | Azioni |
| Nuveen Asset Management, LLC | $18.252.629 | 548.127 | 0,20% | Azioni |
| NFJ INVESTMENT GROUP, LLC | $17.880.160 | 328.619 | 0,20% | Azioni |
| SAWGRASS ASSET MANAGEMENT LLC | $17.808.447 | 327.301 | 0,20% | Azioni |
| WORLDQUANT MILLENNIUM ADVISORS LLC | $17.565.616 | 322.838 | 0,19% | Azioni |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $17.472.485 | 407.379 | 0,19% | Azioni |
| ING GROEP NV | $16.943.274 | 311.400 | 0,19% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $16.529.758 | 303.800 | 0,18% | Opzione Put |
| Brandywine Global Investment Management, LLC | $16.490.117 | 376.229 | 0,18% | Azioni |
| CAPTRUST FINANCIAL ADVISORS | $16.488.532 | 303.042 | 0,18% | Azioni |
| INTECH INVESTMENT MANAGEMENT LLC | $16.262.224 | 298.883 | 0,18% | Azioni |
| HighTower Advisors, LLC | $15.842.121 | 291.162 | 0,17% | Azioni |
| SEIZERT CAPITAL PARTNERS, LLC | $15.411.796 | 283.253 | 0,17% | Azioni |
| Trexquant Investment LP | $14.974.122 | 275.209 | 0,16% | Azioni |
| Clark Capital Management Group, Inc. | $14.792.882 | 271.878 | 0,16% | Azioni |
| ALLIANCEBERNSTEIN L.P. | $14.763.381 | 344.215 | 0,16% | Azioni |
| VAN ECK ASSOCIATES CORP | $14.270.709 | 262.281 | 0,16% | Azioni |
| GLOBEFLEX CAPITAL L P | $13.874.169 | 254.993 | 0,15% | Azioni |
| Sofinnova Investments, Inc. | $13.831.022 | 254.200 | 0,15% | Opzione Put |
| JANE STREET GROUP, LLC | $13.815.570 | 253.916 | 0,15% | Azioni |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $13.724.052 | 252.234 | 0,15% | Azioni |
| Voleon Capital Management LP | $13.682.047 | 251.462 | 0,15% | Azioni |
| BLAIR WILLIAM & CO/IL | $13.233.352 | 243.215 | 0,15% | Azioni |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $13.027.000 | 239.418 | 0,14% | Azioni |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $12.745.021 | 297.156 | 0,14% | Azioni |
| MERITAGE PORTFOLIO MANAGEMENT | $12.679.099 | 289.279 | 0,14% | Azioni |
| VANGUARD ASSET MANAGEMENT, Ltd | $12.516.694 | 230.044 | 0,14% | Azioni |
| Susquehanna Portfolio Strategies, LLC | $12.500.643 | 229.749 | 0,14% | Azioni |
| MILLENNIUM MANAGEMENT LLC | $12.035.492 | 221.200 | 0,13% | Opzione Call |
| Illinois Municipal Retirement Fund | $11.750.764 | 215.967 | 0,13% | Azioni |
| CWM, LLC | $11.300.486 | 263.476 | 0,12% | Azioni |
Insider aziendali 43 insider · 22 dirigenti · 10 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Michael Morrissey | President and CEO | 18 Maggio 2026 G | 2.004.327 | 0 | 0 | $0 |
| Christopher J. Senner | EVP and CFO | 18 Maggio 2026 S | 952.317 | 0 | 3 | $-4.556.048 |
| Deborah Burke | SVP & Chief Financial Officer | 15 Novembre 2014 M | 18.156 | 0 | 0 | $0 |
| Frank Karbe | EVP and CFO | 15 Febbraio 2014 M | 93.990 | 0 | 0 | $0 |
| Kristine M Ball | Controller & Interim CFO | 10 Dicembre 2003 A | 4.913 | 0 | 0 | $0 |
| Patrick J. Haley | EVP, Commercial | 20 Maggio 2026 S | 357.638 | 0 | 7 | $-7.597.268 |
| Brenda Hefti | SVP and General Counsel | 18 Maggio 2026 S | 106.762 | 0 | 2 | $-1.154.264 |
| Amy C. Peterson | EVP Prod Dev & Med Aff & CMO | 16 Maggio 2025 M | 465.393 | 0 | 0 | $0 |
| Jeffrey Hessekiel | EVP & General Counsel | 15 Maggio 2025 S | 693.396 | 0 | 0 | $0 |
| Vicki L Goodman | EVP, Prod Dev & Med Aff &CMO | 03 Aprile 2023 A | 307.654 | 0 | 0 | $0 |
| Peter Lamb | EVP, Scientific Strategy & CSO | 15 Dicembre 2022 M | 410.958 | 0 | 0 | $0 |
| Gisela Schwab | Pres, Prod Dev & Med Aff & CMO | 26 Luglio 2021 M | 689.078 | 0 | 0 | $0 |
| Pamela A Simonton | EVP and General Counsel | 15 Novembre 2013 M | 17.139 | 0 | 0 | $0 |
| Lupe M Rivera | EVP, Operations | 15 Agosto 2011 M | 19.219 | 0 | 0 | $0 |
| Frances K Heller | EVP, Business Development | 15 Maggio 2011 M | 17.125 | 0 | 0 | $0 |
| Ian D Malcolm | VP, STRATEGIC MARKETING | 08 Dicembre 2006 A | — | 0 | 0 | $0 |
| Christoph Pereira | VP, Legal Affairs & Secretary | 08 Dicembre 2006 A | — | 0 | 0 | $0 |
| Jeffrey Latts | Executive VP, Development | 08 Dicembre 2006 A | — | 0 | 0 | $0 |
| Gregory Plowman | Sr VP, CSO | 13 Dicembre 2004 A | — | 0 | 0 | $0 |
| Steven P James | Sr VP, Commercial Ops | 10 Dicembre 2003 A | — | 0 | 0 | $0 |
| Jane M Green | VP, Corp Communications | 10 Dicembre 2003 A | — | 0 | 0 | $0 |
| Geoffrey M Duyk | Pres R&D & CSO | 04 Novembre 2003 S | 941.355 | 0 | 0 | $0 |
| Alan M Garber | Direttore | 21 Marzo 2024 M | 35.703 | 0 | 0 | $0 |
| Jacqueline Wright | Direttore | 01 Giugno 2023 A | 51.756 | 0 | 0 | $0 |
| Carl B Feldbaum | Direttore | 09 Febbraio 2023 M | 18.701 | 0 | 0 | $0 |
| Lance Willsey | Direttore | 26 Maggio 2022 A | 424.415 | 0 | 0 | $0 |
| Vincent T Marchesi | Direttore | 26 Maggio 2022 A | 93.989 | 0 | 0 | $0 |
| Charles Cohen | Direttore | 06 Luglio 2021 M | 261.375 | 0 | 0 | $0 |
| George A Scangos | Direttore | 18 Maggio 2020 S | 714.717 | 0 | 0 | $0 |
| FORMELA JEAN FRANCOIS | Direttore | 07 Settembre 2005 S | 584.519 | 0 | 0 | $0 |
| Mary C Beckerle | — | 10 Agosto 2026 S | 16.079 | 0 | 4 | $-1.932.572 |
| Sue Gail Eckhardt | — | 01 Giugno 2026 S | 16.079 | 0 | 2 | $-660.828 |
| Jack L Wyszomierski | — | 01 Giugno 2026 S | 284.384 | 0 | 2 | $-4.580.661 |
| Tomas J. Heyman | — | 27 Maggio 2026 A | 50.649 | 0 | 0 | $0 |
| Bob Oliver | — | 27 Maggio 2026 A | 29.487 | 0 | 2 | $-1.325.340 |
| Julie Smith | — | 27 Maggio 2026 A | 28.957 | 0 | 3 | $-4.687.346 |
| Maria C Freire | — | 27 Maggio 2026 A | 109.186 | 0 | 1 | $-949.164 |
| Stelios Papadopoulos | — | 27 Maggio 2026 A | 1.197.595 | 0 | 1 | $-4.355.000 |
| George Poste | — | 27 Maggio 2026 A | 127.199 | 0 | 1 | $-2.742.600 |
| Dana Aftab | — | 26 Maggio 2026 S | 594.741 | 0 | 4 | $-7.701.255 |
| Frank Mccormick | — | 06 Dicembre 2013 A | — | 0 | 0 | $0 |
| Scott J. Garland | — | 18 Settembre 2013 A | — | 0 | 0 | $0 |
| Jason S Fisherman | — | 08 Settembre 2005 S | 7.881 | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Attivisti e proprietari del 5%+ 4 partecipazioni
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| Farallon Capital Management, L.L.C., Farallon Capital Partners, L.P., Farallon Capital Institutional Partners, L.P., Farallon Capital Institutional Partners II, L.P., Farallon Capital Institutional Partners III, L.P., Four Crossings Institutional Partners V, L.P., Farallon Capital Offshore Investors II, L.P., Farallon Capital (AM) Investors, L.P., Farallon Capital F5 Master I, L.P., Farallon Healthcare Partners Master, L.P., Farallon Partners, L.L.C., Farallon Institutional (GP) V, L.L.C., Farallon F5 (GP), L.L.C., Farallon Healthcare Partners (GP), L.L.C., Dapice Joshua J., Dreyfuss, Philip D., Dunn Hannah E., Gehani, Varun N., Giauque, Nicolas, Husen, Avner A., Kim, David T., Linn, Michael G., Luo Patrick (Cheng), Roberts, Jr., Thomas G., Saito Edric C., Short Daniel S., Spokes, Andrew J. M., Warren, John R., Wehrly, Mark C. | 14 Agosto 2026 | 5,60% | Modifica | — | SEC |
| Farallon Capital Partners, L.P., Farallon Capital Institutional Partners, L.P., Farallon Capital Institutional Partners II, L.P., Farallon Capital Institutional Partners III, L.P., Four Crossings Institutional Partners V, L.P., Farallon Capital Offshore Investors II, L.P., Farallon Capital (AM) Investors, L.P., Farallon Capital F5 Master I, L.P., Farallon Healthcare Partners Master, L.P., Farallon Partners, L.L.C., Farallon Institutional (GP) V, L.L.C., Farallon F5 (GP), L.L.C., Farallon Healthcare Partners (GP), L.L.C., Dapice Joshua J., Dreyfuss, Philip D., Dunn Hannah E., Fried, Richard B, Gehani, Varun N., Giauque, Nicolas, Husen, Avner A., Kim, David T., Linn, Michael G., Luo Patrick (Cheng), Patel, Rajiv A., Roberts, Jr., Thomas G., Saito Edric C., Seybold, William, Short Daniel S., Spokes, Andrew J. M., Warren, John R., Wehrly, Mark C. ×8 depositi | 05 Gennaio 2026 | 5,90% | Modifica | — | SEC |
| Caligan Partners LP, David Johnson ×3 depositi | 02 Giugno 2023 | — | Deposito iniziale | — | SEC |
| Persona segnalante non divulgata | 29 Novembre 2001 | — | Deposito iniziale | M&A / vendita | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Proprietà ETF Posseduti da 152 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| IDNA · iShares Trust | 3,47% | 131.275 SH | 08 Agosto 2026 | Giornaliero |
| SAWG · ETF Series Solutions | 2,82% | 1.599 NS | 30 Aprile 2026 | N-PORT |
| CANC · Tema ETF Trust | 2,78% | 96.885 NS | 31 Maggio 2026 | N-PORT |
| XMHQ · Invesco Exchange-Traded Fund Trust | 2,67% | 2.774.135 SH | 08 Agosto 2026 | Giornaliero |
| PBE · Invesco Exchange-Traded Fund Trust | 2,59% | 173.519 SH | 08 Agosto 2026 | Giornaliero |
| MCOW · Pacer Funds Trust | 2,38% | 528 NS | 30 Aprile 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 2,24% | 441.186 NS | 30 Aprile 2026 | N-PORT |
| LYLD · Cambria ETF Trust | 2,01% | 2.722 NS | 30 Aprile 2026 | N-PORT |
| AZTD · Tidal Trust I | 1,92% | 18.950 NS | 30 Aprile 2026 | N-PORT |
| GRPM · Invesco Exchange-Traded Fund Trust | 1,84% | 172.947 SH | 08 Agosto 2026 | Giornaliero |
| BBP · ETFis Series Trust I | 1,74% | 23.148 NS | 30 Aprile 2026 | N-PORT |
| ABOT · Abacus FCF ETF Trust | 1,61% | 1.596 NS | 30 Aprile 2026 | N-PORT |
| BUL · Pacer Funds Trust | 1,45% | 41.520 NS | 30 Aprile 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 1,39% | 306.870 NS | 30 Aprile 2026 | N-PORT |
| JMID · Janus Detroit Street Trust | 1,36% | 5.563 NS | 30 Aprile 2026 | N-PORT |
| RFG · Invesco Exchange-Traded Fund Trust | 1,30% | 86.397 SH | 08 Agosto 2026 | Giornaliero |
| PTH · Invesco Exchange-Traded Fund Trust | 1,29% | 58.887 SH | 08 Agosto 2026 | Giornaliero |
| COWG · Pacer Funds Trust | 1,26% | 616.432 NS | 30 Aprile 2026 | N-PORT |
| TAX · EA Series Trust | 1,13% | 5.692 NS | 29 Maggio 2026 | N-PORT |
| CALF · Pacer Funds Trust | 1,07% | 829.382 NS | 30 Aprile 2026 | N-PORT |
| AFMC · First Trust Exchange-Traded Fund VI… | 1,03% | 32.938 NS | 31 Maggio 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 1,00% | 116.281 NS | 30 Aprile 2026 | N-PORT |
| IBB · iShares Trust | 0,98% | 1.788.613 SH | 08 Agosto 2026 | Giornaliero |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,93% | 13.681 SH | 08 Agosto 2026 | Giornaliero |
| AGNG · Global X Funds | 0,92% | 14.988 NS | 31 Maggio 2026 | N-PORT |
| OASC · Unified Series Trust | 0,91% | 15.171 NS | 31 Maggio 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,90% | 25.550 NS | 30 Aprile 2026 | N-PORT |
| FLOW · Global X Funds | 0,90% | 5.093 NS | 31 Maggio 2026 | N-PORT |
| VAMO · Cambria ETF Trust | 0,88% | 16.470 NS | 30 Aprile 2026 | N-PORT |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,72% | 248.016 SH | 08 Agosto 2026 | Giornaliero |
| FLRG · FIDELITY COVINGTON TRUST | 0,72% | 45.672 NS | 30 Aprile 2026 | N-PORT |
| IJK · iShares Trust | 0,70% | 1.469.020 SH | 08 Agosto 2026 | Giornaliero |
| MMSC · First Trust Exchange-Traded Fund VI… | 0,69% | 7.149 NS | 31 Maggio 2026 | N-PORT |
| CLSE · Trust for Professional Managers | 0,68% | 82.717 NS | 31 Maggio 2026 | N-PORT |
| BIB · ProShares Trust | 0,66% | 9.600 NS | 31 Maggio 2026 | N-PORT |
| TMFX · RBB Fund, Inc. | 0,64% | 4.091 NS | 31 Maggio 2026 | N-PORT |
| VUSE · ETF Series Solutions | 0,63% | 85.930 NS | 31 Maggio 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,60% | 2.080 NS | 30 Aprile 2026 | N-PORT |
| PDP · Invesco Exchange-Traded Fund Trust | 0,59% | 165.207 SH | 08 Agosto 2026 | Giornaliero |
| QGRO · AMERICAN CENTURY ETF TRUST | 0,58% | 255.026 NS | 31 Maggio 2026 | N-PORT |
| SIXL · EXCHANGE TRADED CONCEPTS TRUST | 0,53% | 19.762 NS | 31 Maggio 2026 | N-PORT |
| VLLU · Harbor ETF Trust | 0,51% | 502 NS | 30 Aprile 2026 | N-PORT |
| VFQY · VANGUARD WELLINGTON FUND | 0,49% | 42.746 SH | 08 Agosto 2026 | Giornaliero |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0,48% | 64.828 NS | 30 Aprile 2026 | N-PORT |
| HQGO · Lattice Strategies Trust | 0,47% | 5.095 NS | 30 Aprile 2026 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 0,45% | 147.282 SH | 08 Agosto 2026 | Giornaliero |
| IQSM · New York Life Investments ETF Trust | 0,44% | 30.864 NS | 30 Aprile 2026 | N-PORT |
| XJH · iShares Trust | 0,41% | 33.981 SH | 08 Agosto 2026 | Giornaliero |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,41% | 47.960 NS | 30 Aprile 2026 | N-PORT |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0,41% | 33.169 SH | 08 Agosto 2026 | Giornaliero |